Evidence map›Paper›PMID 31123906›Full record

ArticleMetabolomics : Official journal of the Metabolomic Society2019

A comprehensive protocol for multiplatform metabolomics analysis in patient-derived skin fibroblasts.

Jordan Wilkins, Dhananjay Sakrikar, Xuan-Mai Petterson, Ian R Lanza, Eugenia Trushina

Open access · greenAbstract read
In one paragraph

Article in Metabolomics : Official journal of the Metabolomic Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. International journal of molecular sciences · 2023
    Article
  13. Chemotherapy-Induced Peripheral Neuropathy.Handbook of experimental pharmacology · 2023
    Article
  14. Article
  15. Journal of diabetes research · 2023
    Article
  16. Current Knowledge in Skin Metabolomics: Updates from Literature Review.International journal of molecular sciences · 2022
    Review
  17. Article
  18. Article
  19. Frontiers in microbiology · 2021
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jordan WilkinsDepartment of Neurology, Mayo Clinic, Rochester, MN, 55905, USA.
Dhananjay SakrikarMetabolomics Core Laboratory, Mayo Clinic, Rochester, MN, 55905, USA.
Xuan-Mai PettersonMetabolomics Core Laboratory, Mayo Clinic, Rochester, MN, 55905, USA.
Ian R LanzaMetabolomics Core Laboratory, Mayo Clinic, Rochester, MN, 55905, USA.
Eugenia TrushinaDepartment of Neurology, Mayo Clinic, Rochester, MN, 55905, USA. trushina.eugenia@mayo.edu.ORCID 0000-0002-6291-2860
Mayo Clinic · US

Funding

TECHNOLOGY NMR SPECTROSCOPYU24DK100469 · NIDDK · MAYO CLINIC ROCHESTER · PI NAIR, K SREEKUMARAN · 2013 to 2017
$9.0M
Mitochondrial Complex I as a Target for Neuroprotection in ADRF1AG055549 · NIA · MAYO CLINIC ROCHESTER · PI TRUSHINA, EUGENIA · 2017 to 2025
$7.0M
Small molecule mitochondria-targeted therapeutics for Huntingtons DiseaseR01NS107265 · NINDS · MAYO CLINIC ROCHESTER · PI TRUSHINA, EUGENIA · 2018 to 2021
$2.2M
Mitochondrial dynamics and metabolomic biomarkers in neurodegenerative disordersR01ES020715 · NIEHS · MAYO CLINIC ROCHESTER · PI TRUSHINA, EUGENIA · 2011 to 2015
$1.8M
Small Molecule Mitochondria-Targeted Therapeutics for AD (Supplement)UH3NS113776 · NINDS · MAYO CLINIC ROCHESTER · PI TRUSHINA, EUGENIA · 2022 to 2022
$1.1M
NIA NIH HHS RF1 AG055549NIDDK NIH HHS U24 DK100469NIEHS NIH HHS R01 ES020715NINDS NIH HHS R01 NS107265NINDS NIH HHS UH3 NS113776
6 · The paper itself

Abstract

introductionPatient-derived skin fibroblasts offer a unique translational model to study molecular mechanisms of multiple human diseases. Metabolomics profiling allows to track changes in a broad range of metabolites and interconnected metabolic pathways that could inform on molecular mechanisms involved in disease development and progression, and on the efficacy of therapeutic interventions. Therefore, it is important to establish standardized protocols for metabolomics analysis in human skin fibroblasts for rigorous and reliable metabolic assessment.

objectivesWe aimed to develop an optimized protocol for concurrent measure of the concentration of amino acids, acylcarnitines, and components of the tricarboxylic acid (TCA) cycle in human skin fibroblasts using gas (GC) and liquid chromatography (LC) coupled with mass spectrometry (MS).

methodsThe suitability of four different methods of cell harvesting on the recovery of amino acids, acylcarnitines, and TCA cycle metabolites was established using GC/MS and LC/MS analytical platforms. For each method, metabolite stability was determined after 48 h, 2 weeks and 1 month of storage at - 80 °C.

resultsHarvesting cells in 80% methanol solution allowed the best recovery and preservation of metabolites. Storage of samples in 80% methanol up to 1  month at - 80 °C did not significantly impact metabolite concentrations.

conclusionWe developed a robust workflow for metabolomics analysis in human skin fibroblasts suitable for a high-throughput multiplatform analysis. This method allows a direct side-by-side comparison of metabolic changes in samples collected at different time that could be used for studies in large patient cohorts.

Indexed as

MetabolomeAmino AcidsCarnitineCells, CulturedChromatography, LiquidCitric Acid CycleFibroblastsGas Chromatography-Mass SpectrometryHumansMetabolomicsSkinacylcarnitineAmino AcidsCarnitineAcylcarnitinesAmino acidsCell harvestingMetabolomicsSkin fibroblastsTCA cycle

Identifiers

PMID31123906
PMCPMC7928486
OpenAlexW2945230966

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.